{
    "eid": "2-s2.0-85134328319",
    "title": "Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy",
    "cover-date": "2022-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Transplantation",
            "@code": "2747",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Kitsada Wudhikarn",
        "Miguel Angel Perales"
    ],
    "citedby-count": 16,
    "ref-count": 111,
    "ref-list": [
        "Chimeric antigen receptor therapy",
        "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma",
        "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma",
        "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study",
        "KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma",
        "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study",
        "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial",
        "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma",
        "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study",
        "Toxicities of chimeric antigen receptor T cells: recognition and management",
        "Beyond the storm\u2014subacute toxicities and late effects in children receiving CAR T cells",
        "Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities",
        "Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy",
        "Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma",
        "Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma",
        "Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells",
        "Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma",
        "Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults",
        "Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days",
        "How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies",
        "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial",
        "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia",
        "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma",
        "Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study",
        "Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial",
        "Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial",
        "Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma",
        "Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells",
        "Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells",
        "Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma",
        "Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma",
        "Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy",
        "Pathogen-specific humoral immunity and infections in B Cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma",
        "Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy. Blood",
        "CMV and HSV pneumonia after immunosuppressive agents for treatment of cytokine release syndrome due to chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy",
        "Intractable Coronavirus Disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study",
        "Coronavirus disease 2019 (COVID-19) and immune-engaging cancer treatment",
        "COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience",
        "Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer",
        "COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP",
        "Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group",
        "Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy\u2014a case report",
        "Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis",
        "Infectious complications in pediatric, adolescent and young adult patients undergoing CD19-CAR T cell therapy",
        "Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children/young adults with relapsed/refractory B cell acute lymphoblastic leukemia",
        "Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia",
        "Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies",
        "CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma",
        "CAR T-cell hematotoxicity: is inflammation the key?",
        "Integrated safety in tocilizumab clinical trials",
        "Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?",
        "Steroid use, advanced stage disease and \u22653 lines of prior chemotherapy are associated with a higher risk of infection following CD19 CAR T-cell therapy for B-NHL: real world data from a large UK center",
        "Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma",
        "Invasive fungal infections after Anti-CD19 chimeric antigen receptor-modified T-cell therapy: State of the evidence and future directions",
        "CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia",
        "Hypogammaglobulinemia due to CAR T-cell therapy",
        "Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies",
        "Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy",
        "New-onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia",
        "Early and late hematologic toxicity following CD19 CAR-T cells",
        "DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality",
        "Cytopenias after chimeric antigen receptor T-Cells (CAR-T) infusion; patterns and outcomes",
        "Cytopenia after CAR-T cell therapy\u2014a brief review of a complex problem",
        "CAR-T-OPENIA: chimeric antigen receptor T-cell therapy-associated cytopenias",
        "Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011)",
        "Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies",
        "Factors associated with impaired hematopoietic recovery after CD19-targeted CAR-T cell therapy",
        "Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells",
        "Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults",
        "KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results",
        "Hypogammaglobulinemia and infection risk in chronic lymphocytic leukemia (CLL) patients treated with CD19-directed chimeric antigen receptor T (CAR-T) Cells",
        "Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy",
        "Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy",
        "Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians",
        "Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper",
        "Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)",
        "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells",
        "T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade",
        "G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma",
        "The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy",
        "Filgrastim associations with CAR T-cell therapy",
        "Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma",
        "Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation",
        "Side-effect management of chimeric antigen receptor (CAR) T-cell therapy",
        "Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)",
        "Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection",
        "Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma",
        "Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection",
        "Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy",
        "Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection",
        "Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus",
        "COVID-19 in patients with hematologic malignancy",
        "Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19",
        "Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies",
        "State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses",
        "Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia",
        "Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis",
        "Immunoglobulin replacement therapy in secondary hypogammaglobulinemia",
        "Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation",
        "Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis",
        "CAR-T - and a side order of IgG, to go?\u2014Immunoglobulin replacement in patients receiving CAR-T cell therapy",
        "Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions",
        "How I vaccinate blood and marrow transplant recipients",
        "Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations",
        "SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: a systematic review and preliminary observations",
        "Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy",
        "Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy",
        "Immune responses to SARS-CoV-2 vaccination in young patients with anti-CD19 CAR-T-induced B-cell aplasia",
        "SARS-CoV-2 spike-specific T-cell responses in patients with B-cell depletion who received chimeric antigen receptor T-cell treatments"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "NIH",
        "NCI"
    ]
}